SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Y. Nasser, M. Bashashati, C. N. Andrews, Toward modulation of the endocannabinoid system for treatment of gastrointestinal disease: FAAHster but not “higher”, Neurogastroenterology & Motility, 2014, 26, 4
  2. 2
    Stefano Guandalini, Authorʼs Response, Journal of Pediatric Gastroenterology and Nutrition, 2012, 54, 1, 109

    CrossRef

  3. 3
    B. S. Wong, M. Camilleri, D. Eckert, P. Carlson, M. Ryks, D. Burton, A. R. Zinsmeister, Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea, Neurogastroenterology & Motility, 2012, 24, 4
  4. You have free access to this content4
    V. Di Marzo, F. Piscitelli, Gut feelings about the endocannabinoid system, Neurogastroenterology & Motility, 2011, 23, 5
  5. 5
    Banny S. Wong, Michael Camilleri, Irene Busciglio, Paula Carlson, Lawrence A. Szarka, Duane Burton, Alan R. Zinsmeister, Pharmacogenetic Trial of a Cannabinoid Agonist Shows Reduced Fasting Colonic Motility in Patients With Nonconstipated Irritable Bowel Syndrome, Gastroenterology, 2011, 141, 5, 1638

    CrossRef

  6. 6
    R. A. Awad, S. Camacho, Reply to Dr Filik, Colorectal Disease, 2011, 13, 11
  7. 7
    Muriel Larauche, Agata Mulak, Yvette Taché, Stress-Related Alterations of Visceral Sensation: Animal Models for Irritable Bowel Syndrome Study, Journal of Neurogastroenterology and Motility, 2011, 17, 3, 213

    CrossRef

  8. 8
    Adam D. Farmer, Madusha Peiris, Qasim Aziz, Gut Hypersensitivity Related Symptoms,
  9. 9
    Paolo Caraceni, Francesca Borrelli, Ferdinando A. Giannone, Angelo A. Izzo, Potential therapeutic applications of cannabinoids in gastrointestinal and liver diseases: Focus on Δ9-tetrahydrocannabinol pharmacology,